AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 191 min read$DNTH

Read Simon sold $327K of DNTH

Read Simon sold 2,778 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at $117.55 ($0.33M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Read Simon
Published Aug 19, 2026, 10:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 10:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$DNTH
Neutral
high confidence
Mentioned
$DNTH
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DNTHNeutralLow
01

Why it matters

The sale is routine and unlikely to move the stock, but repeated sales could erode confidence.

02

Market read

Low relevance; typical insider sell with modest dollar amount.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 4/10Timing: 2026-08-19 filing date

Background

Form 4 filings disclose insider transactions; investors watch for trends in insider buying or selling.

Company-level read

Ticker impact

$DNTHNeutralHigh confidence
Context

Director Read Simon sold 2,778 shares for $326,554 via a 10b5-1 plan, reducing his holding to zero.

Expected impact

No significant move expected.

Evidence & confidence

Sale size is small relative to market cap and disclosed via Form 4, typical routine insider transaction.

Market effects

Sector

None; biotech sector unaffected by this isolated insider sale.

Regional

No regional impact.

Global

Minimal.

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor for further disposals.

Key entities

  • Company
    Dianthus Therapeutics, Inc.

    Biotech firm developing therapies for rare diseases.

  • Insider
    Read Simon

    Director of Dianthus Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DNTH insider trading history →

Related articles

SEP 5
$DNTHMedAI 8/10

Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen

Dianthus Therapeutics (DNTH) reported Q2 2026 results, highlighting clinical trial progress. Claseprubart showed a 75% response rate in a Phase 3 trial for chronic inflammatory demyelinating polyneuropathy. The company also advanced trials for multifocal motor neuropathy and generalized myasthenia gravis. R&D costs rose to $48.7M, with a net loss of $50.2M. DNTH has $1.2B in cash, funding operations into 2030.

yahoo.com2 min
AUG 4
$DNTHMed

DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q2 2026 FINANCIAL RESULTS

Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q2 2026 FINANCIAL RESULTS Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized M

SEC EDGAR 8-K7 min